...
首页> 外文期刊>Theranostics >Injectable and in situ crosslinkable gelatin microribbon hydrogels for stem cell delivery and bone regeneration in vivo
【24h】

Injectable and in situ crosslinkable gelatin microribbon hydrogels for stem cell delivery and bone regeneration in vivo

机译:用于干细胞输送和体内骨再生的可注射和原位交联明胶水凝胶

获取原文
           

摘要

Rationale: Injectable matrices are highly desirable for stem cell delivery. Previous research has highlighted the benefit of scaffold macroporosity in enhancing stem cell survival and bone regeneration in vivo. However, there remains a lack of injectable and in situ crosslinkable macroporous matrices for stem cell delivery to achieve fast bone regeneration in immunocompetent animal model. The goal of this study is to develop an injectable gelatin-based μRB hydrogel supporting direct cell encapsulation that is available in clinics as macroporous matrices to enhance adipose-derived stromal cell (ASC) survival, engraftment and accelerate bone formation in craniofacial defect mouse. Methods: Injectable and in situ crosslinkable gelatin microribbon (μRB)-based macroporous hydrogels were developed by wet-spinning. Injectability was optimized by varying concentration of glutaraldehyde for intracrosslinking of μRB shape, and fibrinogen coating. The efficacy of injectable μRBs to support ASCs delivery and bone regeneration were further assessed in vivo using an immunocompetent mouse cranial defect model. ASCs survival was evaluated by bioluminescent imaging and bone regeneration was assessed by micro-CT. The degradation and biocompatibility were determined by histological analysis. Results: We first optimized injectability by varying concentration of glutaraldehyde used to fix gelatin μRBs. The injectable μRB formulation were subsequently coated with fibrinogen, which allows in situ crosslinking by thrombin. Fluorescence imaging and histology showed majority of μRBs degraded by the end of 3 weeks. Injectable μRBs supported comparable level of ASC proliferation and bone regeneration as implantable prefabricated μRB controls. Adding low dosage of BMP2 (100 ng per scaffold) with ASCs substantially accelerated the speed of mineralized bone regeneration, with 90% of the bone defect refilled by week 8. Immunostaining showed M1 (pro-inflammatory) macrophages were recruited to the defect at day 3, and was replaced by M2 (anti-inflammatory) macrophages by week 2. Adding μRBs or BMP2 did not alter macrophage response. Injectable μRBs supported vascularization, and BMP-2 further enhanced vascularization. Conclusions: Our results demonstrated that μRB-based scaffolds enhanced ASC survival and accelerated bone regeneration after injection into critical sized cranial defect mouse. Such injectable μRB-based scaffold can provide a versatile biomaterial for delivering various stem cell types and enhancing tissue regeneration.? The author(s).
机译:理由:可注射矩阵非常希望干细胞输送。以前的研究突出了支架宏观度在增强体内干细胞存活和骨再生方面的益处。然而,仍然缺乏可注射的可注射和原位交联的大孔矩阵,用于干细胞输送,以实现免疫活性动物模型中的快速骨再生。该研究的目的是开发一种基于明胶基水凝胶,其支持直接细胞包封,其可在临床中获得作为大孔基质,以增强脂肪衍生的基质细胞(ASC)存活,植入和加速颅面缺陷小鼠中的骨形成。方法:通过湿法纺丝开发出可注射和原位可交联的明胶微胶(μRB)的大孔水凝胶。通过改变戊二醛的浓度来优化可注射性,用于鞘内连接的μRB形状和纤维蛋白原涂层。使用免疫活性小鼠颅缺陷模型进一步在体内进一步评估可注射μrB以支持ASCS递送和骨再生的疗效。通过生物发光成像评估ASCS存活,通过微型CT评估骨再生。通过组织学分析确定降解和生物相容性。结果:我们首先通过改变用于固定明胶μRB的戊二醛的浓度优化可注射性。随后用纤维蛋白原涂覆可注射的μRB制剂,其允许通过凝血酶原位交联。荧光成像和组织学显示大部分μRBs在3周末降解。可注射的μRBS支持的ASC增殖和骨再生水平作为可植入预制的μRB对照。添加低剂量的BMP2(每个支架)的BMP2(每支架100ng)基本上加速了矿化骨再生的速度,90%的骨缺损在第8周内重新填充。免疫染色显示M1(促炎)巨噬细胞在一天招募到缺陷3,并被M2(抗炎)巨噬细胞替换为第2周。添加μRB或BMP2未改变巨噬细胞反应。可注射的μRBS负载血管化,BMP-2进一步增强血管化。结论:我们的研究结果表明,基于μRB的支架增强了注射到临界大小的颅缺陷鼠中的ASC存活率和加速骨再生。这种可注射的μRB基支架可以提供通用的生物材料,用于递送各种干细胞类型并增强组织再生。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号